◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SMMT

Summit Therapeutics PLC (SMMT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-07-25

Summit Therapeutics PLC (SMMT) operates in the BIOTECHNOLOGY industry and is headquartered in Miami, United States with about 265 employees. Its market capitalization is roughly $14 billion. In the fiscal year ended 2025-12-31, SMMT reported $0M in revenue and ($1.1B) in net income.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Interactive charts & full statements →

SMMT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$0M	$0M	$0M	$0M	$1M	$2M	$1M	$43M	$57M	$14M	$2M	$1M	$2M	$2M	$2M	$1M	$1M	$0M	$0M	$6M	$2M
Gross Profit	—	$0M	($15M)	($2M)	$1M	$2M	$1M	$43M	$56M	$14M	$2M	$1M	$2M	$2M	$2M	$1M	$0M	($2M)	$0M	$0M	$1M
Gross Margin %	—	—	—	—	100.0%	100.0%	100.0%	100.0%	98.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	41.1%	-706.9%	97.8%	1.9%	70.6%
Operating Income (EBIT)	($875M)	($1.1B)	($181M)	($478M)	($60M)	($86M)	($72M)	$15M	$5M	($26M)	($25M)	($20M)	($12M)	($7M)	($5M)	($5M)	($9M)	($9M)	($19M)	($23M)	($9M)
Operating Margin %	—	—	—	—	-10225.4%	-4764.3%	-11392.7%	35.2%	9.4%	-182.3%	-1046.0%	-1588.3%	-647.9%	-363.8%	-241.5%	-422.3%	-1270.0%	-3047.6%	-7198.9%	-388.5%	-423.8%
Net Income	($856M)	($1.1B)	($177M)	($482M)	($65M)	($86M)	($39M)	$5M	$11M	($20M)	($21M)	($20M)	($11M)	($6M)	($4M)	($4M)	($7M)	($5M)	($32M)	($20M)	($6M)
Net Margin %	—	—	—	—	-11174.8%	-4762.1%	-6127.6%	11.6%	19.0%	-142.3%	-899.5%	-1572.0%	-603.0%	-330.4%	-223.0%	-379.0%	-1004.6%	-1769.2%	-12109.6%	-334.1%	-292.1%
EBITDA	—	($1.1B)	($168M)	($69M)	($52M)	($84M)	($37M)	$16M	$12M	($26M)	($25M)	($20M)	($12M)	($7M)	($4M)	($2M)	($9M)	($5M)	($16M)	($19M)	($6M)
Earnings Per Share (EPS)	$-1.12	$-1.44	$-0.25	$-0.78	$-0.34	$-0.93	$-0.55	$0.15	$0.13	$-0.31	$-0.35	$-0.34	$-0.29	$-0.30	$-0.27	$-0.02	$-0.19	$-0.08	$-0.60	$-0.42	$-0.16
Shares Outstanding (M)	778M	748M	719M	620M	193M	92M	70M	33M	86M	65M	62M	59M	40M	21M	—	178M	38M	67M	53M	48M	36M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMMT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	—	$0M	$0M	—	$0M	$0M	($15M)	$0M
Gross Margin %	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($220M)	($195M)	($225M)	($234M)	($234M)	($52M)	($52M)	($44M)
Operating Margin %	—	—	—	—	—	—	—	—
Net Income	($216M)	($189M)	($219M)	($232M)	($232M)	($49M)	($49M)	($42M)
Net Margin %	—	—	—	—	—	—	—	—
EBITDA	($216M)	($189M)	($219M)	—	($232M)	($49M)	($49M)	($40M)
Earnings Per Share (EPS)	$-0.28	$-0.24	$-0.29	$-0.31	$-0.31	$-0.07	$-0.07	$-0.06
Shares Outstanding (M)	778M	775M	766M	744M	743M	738M	738M	727M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMMT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($429M)	($240M)	($114M)	($61M)	($34M)	($54M)	($35M)	($27M)	($35M)	($21M)	$15M	($24M)	($17M)	($10M)	($5M)	($4M)	($4M)	($3M)	($15M)	($16M)	($6M)
Capital Expenditures (CapEx)	$1M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$2M	$4M	$3M
Free Cash Flow (FCF)	($431M)	($240M)	($114M)	($61M)	($34M)	($54M)	($36M)	($27M)	($35M)	($21M)	$15M	($25M)	($17M)	($10M)	($5M)	($4M)	($5M)	($3M)	($16M)	($20M)	($9M)
FCF Margin %	—	—	—	—	-5899.6%	-2986.9%	-5668.4%	-62.6%	-61.8%	-150.0%	634.1%	-1917.6%	-881.4%	-529.2%	-272.0%	-357.6%	-613.0%	-922.7%	-6141.1%	-331.8%	-460.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMMT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($168M)	($93M)	($76M)	($93M)	($69M)	($47M)	($39M)	($23M)
Capital Expenditures (CapEx)	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($169M)	($93M)	($76M)	($93M)	($69M)	($48M)	($39M)	($23M)
FCF Margin %	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMMT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$752M	$557M	$348M	$161M	$541M	$84M	$75M	$75M	$80M	$76M	$47M	$36M	$29M	$12M	$7M	$6M	$8M	$18M	$20M	$69M	$46M
Cash & Cash Equivalents	$419M	$167M	$84M	$57M	$284M	$53M	$49M	$50M	$35M	$28M	$35M	$23M	$17M	$3M	$5M	$3M	$5M	$10M	$4M	$20M	$36M
Total Liabilities	$122M	$69M	$37M	$99M	$438M	$22M	$17M	$14M	$24M	$62M	$51M	$6M	$10M	$4M	$2M	$2M	$2M	$5M	$8M	$15M	$6M
Total Debt (Short + Long-Term)	$4M	$3M	$3M	$102M	$512M	$1M	$0M	($1M)	$0M	$18M	$5M	$5M	$0M	$0M	$2M	$1M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$630M	$489M	$311M	$61M	$103M	$62M	$58M	$61M	$56M	$14M	($4M)	$30M	$20M	$8M	$5M	$4M	$6M	$13M	$12M	$54M	$40M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SMMT viewer.

SMMT Metric Deep Dives

Other Companies in BIOTECHNOLOGY

GMAB · Genmab AS — $21 billion
JAZZ · Jazz Pharmaceuticals PLC — $16 billion
ASND · Ascendis Pharma AS — $16 billion
EXEL · Exelixis Inc — $14 billion
BBIO · BridgeBio Pharma Inc — $13 billion
HALO · Halozyme Therapeutics Inc — $13 billion
BMRN · Biomarin Pharmaceutical Inc — $12 billion
MDGL · Madrigal Pharmaceuticals Inc — $12 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← SMMD All “S” companies SMMU →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.